US high court’s ‘skinny label’ decision may not chill market as generics warn
Generic and biosimilar manufacturers and the US Solicitor General have warned that a Supreme Court holding against Hikma Pharmaceuticals could dismantle the generic drug market. But with so-called “skinny labels” affixed...To view the full article, register now.
Already a subscriber? Click here to view full article